Despite these promising biomarker findings, very little is known about the association between GFAP levels in the brain and AD neuropathology, or whether upregulation of GFAP in the blood reflects upregulation in the brain, making the interpretation of plasma GFAP challenging. This evidence concerns the gene GFAP and Alzheimer disease.